<DOC>
	<DOCNO>NCT01802775</DOCNO>
	<brief_summary>This study randomize , open-label , blind endpoint , parallel-group , active-control , multi-center , proof-of-concept study subject Peripheral Arterial Disease ( PAD ) , design ass safety potential efficacy add edoxaban aspirin follow femoropopliteal endovascular intervention , without stent placement , relative current treatment practice clopidogrel aspirin .</brief_summary>
	<brief_title>Edoxaban Peripheral Arterial Disease</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Male female subject older minimum legal adult age ( country specific ) ; Rutherford stag 25 provided ulceration heel and/or expose tendon and/or bone ; Superficial femoral kneepopliteal ( 3 cm proximal medial femoral condyle ) lesion ≥ 50 % stenosis occlusion ; At least one runoff vessel foot without additional endovascular intervention ; Successful intervention , define angiographic confirmation ≤ 30 % residual stenosis absence flow limit dissection ; Adequate hemostasis vascular access site within 24 hour intervention ; A subject also eligible undergone additional successful endovascular intervention ( ) index intervention ; Able provide sign informed consent . Calculated Creatinine Clearance &lt; 30 ml/min ; Femoral popliteal aneurysm ; Adjunctive use thrombolytic ; Any extravasation distal embolization successfully treat ; Uncontrolled hypertension judge investigator ( e.g. , systolic blood pressure &gt; 170 mmHg diastolic blood pressure &gt; 100 mmHg despite antihypertensive ) ; Aspirin intolerance ; Clopidogrel intolerance ; Contraindication anticoagulant antiplatelets contraindication list local labeling aspirin and/or clopidogrel ; Active bleed know high risk bleed history intracranial , spontaneous intraocular , spinal retroperitoneal intraarticular bleeding ; overt gastrointestinal ( GI ) bleed active ulcer within previous year ; Subjects receive dual antiplatelet anticoagulant therapy time randomization ; subject receive preinterventional loading dose clopidogrel P2Y12 receptor antagonist ; Treatment cilostazol within 24 hour randomization ; Subjects receive prohibit concomitant medication [ fibrinolytics , chronic use non steroidal antiinflammatory drug ( NSAIDS ) &gt; 4 day per week , oral parenteral nonaspirin NSAIDs strong Pgp inhibitor ] ; Prior stroke MI acute coronary syndrome within 3 month ; Chronic liver disease [ alanine transaminase ( ALT ) and/or aspartate transaminase ( AST ) ≥ 2 × upper limit normal ; total bilirubin ( TBL ) ≥ 1.5 × upper limit normal ] ; however , subject whose elevated TBL due know Gilbert‟s syndrome may include study ; Prior history positive test Hepatitis B antigen Hepatitis C antibody ; Subjects receive investigational drug device within 30 day prior randomization , plan receive investigational therapy study period ; Subjects previously randomize edoxaban ( DU176b ) study ; Women childbearing potential without proper contraceptive measure ( i.e . method contraception failure rate &lt; 1 % course study include observational period ) woman pregnant breast feeding ; Subjects follow diagnosis situation : Active malignancy except adequately treat nonmelanoma skin cancer noninvasive insitu neoplasm ( e.g. , cervical cancer situ ) ; Concurrent treatment cancer therapy ( drug , radiation , and/or surgery ) ; Other significant active concurrent medical illness infection ; Life expectancy &lt; 12 month ; Subjects unlikely comply protocol ( e.g. , uncooperative attitude , inability return subsequent visit , and/or otherwise consider Investigator unlikely complete study ) ; Subjects condition , opinion Investigator , would place subject increase risk harm he/she participate study ; History heparininduced thrombocytopenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>